There is a moment in 2009 that, in hindsight, changed the trajectory of modern medicine. Derrick Rossi, a stem cell biologist at Harvard Medical School, was working late in his lab on a problem that had fascinated — and frustrated — scientists for decades: how to reprogram adult human cells to behave like embryonic stem cells, the kind that can theoretically become any tissue in the body. The holy grail of regenerative medicine. The kind of breakthrough that wins Nobel Prizes.
Rossi cracked it. And the tool he used was something called messenger RNA.
In 2009, Rossi successfully used mRNA technology to reprogram adult cells to act like embryonic stem cells — specialized cells that can turn into any other cell in the body. It was a stunning result. But Rossi, to his credit, understood immediately that the implications extended far beyond stem cell biology. If you could use mRNA to give a cell new instructions — any instructions — the applications were essentially limitless. You could tell cells to produce proteins they wouldn’t normally make. You could instruct the immune system to recognize and attack specific threats. You could, in theory, program the human body like software.
He showed his work to a colleague. That colleague introduced him to Robert Langer, the legendary MIT biomedical engineer who holds more than 800 patents and is widely considered one of the most influential scientists of the last century. Langer recognized the potential impact that Rossi’s work could have on the future of biomedicine. Within days, the men enlisted money from venture capitalist Noubar Afeyan to fund a start-up company.
That startup was Moderna. And what followed is one of the most dramatic business stories Boston has ever produced.
The Stealth Years: Building Something Nobody Had Ever Built
Moderna was founded in 2010 by Derrick Rossi, Noubar Afeyan, and Robert Langer through Flagship Pioneering, initially codenamed LS18 inside the venture studio before being renamed Moderna Therapeutics to reflect its focus on modified RNA technologies. The name itself is a portmanteau — MODified RNA — and it captured the company’s core bet: that messenger RNA could be engineered into an entirely new class of medicine.
The early strategy involved a strong focus on research and development, operating in “stealth mode” for its first two years. No products. No public announcements. No proof that any of it would work in humans. Just a small team of scientists in Cambridge, burning through capital, trying to solve problems that had never been solved before.
The biggest problem was stability. mRNA is inherently fragile — it degrades quickly inside the body, and the immune system tends to react to foreign mRNA as if it were a pathogen. Moderna had to overcome significant technical challenges related to mRNA stability before any of this could become medicine. The solution involved a combination of chemical modifications to the mRNA molecule itself and a sophisticated lipid nanoparticle delivery system — essentially a tiny fat bubble that protects the mRNA long enough to get it into cells.
Despite having nothing on the market — not a single approved product, not a single published clinical result — Moderna was raising money at a pace that stunned the industry. Between 2011 and 2017, Moderna raised $2 billion in venture capital funding. Investors were betting not on a drug but on a platform — the idea that if the underlying mRNA technology worked, Moderna could theoretically develop vaccines and therapies for almost any disease, faster and cheaper than traditional methods allowed.
It was one of the boldest bets in biotech history. And for years, nobody outside a small circle of scientists and investors even knew it was being made.
The IPO That Broke Records — and the Skeptics Who Were Right to Be Skeptical
By 2018, Moderna had been operating for eight years without a single approved product. It had partnered with AstraZeneca, with Merck, with the Bill & Melinda Gates Foundation. It had received a $25 million DARPA grant to develop pandemic-response capabilities. It had a pipeline of candidates for everything from heart disease to HIV. But it had never proven, in a large human trial, that its core technology actually worked.
That did not stop it from going public. In December 2018, Moderna became a public company via the largest initial public offering of a biotechnology company in history, raising $621 million. The valuation was staggering for a company with no approved products. Critics were vocal. Skeptics called it a house of cards. Some analysts openly questioned whether the mRNA platform would ever produce anything commercially viable.
They were asking a fair question. And then a bat in Wuhan answered it for them.
63 Days: The Moment Everything Changed
On January 11, 2020, Chinese scientists published the genetic sequence of a novel coronavirus that was spreading in Wuhan. The world would spend the next several months slowly grasping what this meant. Moderna spent that time building a vaccine.
The first participant in the NIAID-led Phase 1 study of Moderna’s COVID-19 vaccine was dosed on March 16 — just 63 days from sequence selection to Phase 1 study dosing. Sixty-three days. In a field where vaccine development typically takes a decade or more, that number was so extraordinary that many people simply didn’t believe it when they first heard it. The speed was possible precisely because of the decade of unglamorous platform work that had preceded it — the mRNA stability research, the lipid nanoparticle delivery system, the manufacturing processes quietly refined over years when no one was watching.
Moderna received $955 million from BARDA, the U.S. government’s biomedical advanced research authority, to fund vaccine development, with total U.S. government investment in the Moderna COVID-19 vaccine reaching $2.5 billion. The Phase 3 trial enrolled 30,000 participants. The results, announced in November 2020, showed 94.5% efficacy against COVID-19.
The Emergency Use Authorization came in December 2020. Within months, Moderna’s vaccine was being administered in arms across the United States, Europe, and dozens of countries worldwide. The company that had spent a decade building something nobody had ever seen before had just delivered one of the most consequential medical products in history — and done it faster than anyone thought was scientifically possible.
The financial consequences were equally extraordinary. Moderna generated $19.26 billion in revenue in 2022 at the peak of COVID-19 vaccine demand — compared to virtually zero commercial revenue just two years earlier. Stéphane Bancel, the French CEO who had joined the company in 2011 as a relative unknown, became one of the most recognizable figures in global healthcare. The scientists, the venture capitalists, and the early employees who had bet on an idea that most of the world had never heard of became extraordinarily wealthy.
The Hangover, the Pivot, and the Next Big Bet
After the peak comes the reckoning. Moderna’s 2025 revenue stood at $1.9 billion — a 40% decline from 2024 — as the world moved toward a seasonal, private-market model for COVID vaccinations. The company reported a net loss of $2.8 billion for the full year. The stock, which had briefly traded above $400 per share during the pandemic frenzy, has spent the years since searching for a new floor.
This is the part of the story that is easy to frame as a fall from grace. But that framing misses what is actually happening in Cambridge right now — which is arguably more interesting than anything Moderna did during the pandemic.
Moderna allocated an anticipated $3.3 to $3.4 billion into R&D in 2025, primarily on late-stage programs like its personalized cancer vaccine. That vaccine — known as mRNA-4157 or intismeran, developed in partnership with Merck — works by analyzing the specific genetic mutations in an individual patient’s tumor and building a custom mRNA vaccine targeting those exact mutations. Each patient gets a different vaccine, engineered specifically for their cancer. In a Phase 2b trial, the personalized mRNA cancer vaccine combined with pembrolizumab reduced post-resection recurrence by 44% and distant metastasis risk by 65% compared to standard treatment alone. Phase 3 trials are now underway across melanoma, non-small cell lung cancer, bladder cancer, and renal cell carcinoma.
Moderna has also built a dedicated manufacturing facility in Marlborough, Massachusetts, purpose-built for its individualized neoantigen therapy, featuring advanced automation and robotics that began clinical batch supply in September 2025. This is not a company coasting on pandemic glory — it is a company that used the pandemic windfall to fund the next chapter.
Moderna ended 2025 with $8.1 billion in cash and investments — a war chest that its leadership describes as the “bridge” to 2028, when the company targets a return to cash-flow breakeven as its oncology and respiratory vaccine portfolios mature. By 2028, Moderna anticipates launching up to six approved seasonal vaccine products, including a first-to-market flu and COVID combination vaccine.
What Moderna Means for Boston
It would be easy to tell Moderna’s story as a national or global story — and it is. But it is also, inescapably, a Boston story. The idea that became Moderna was born in a Harvard lab. It was incubated by a Cambridge venture studio. It was built by researchers who commuted to Kendall Square. The manufacturing facilities that produced hundreds of millions of doses are in Massachusetts.
And the scientists who are now racing to build a personalized cancer vaccine — one that could potentially do for oncology what the COVID vaccine did for infectious disease — are doing that work a few miles from the same lab where Derrick Rossi stayed late one night in 2009 and figured out how to rewrite the instructions inside a human cell.
That is the thing about Boston’s biotech ecosystem that the numbers only partially capture. The breakthroughs do not come from nowhere. They come from a city that has spent decades building the conditions for exactly this kind of impossible-seeming thing to become real.
Moderna was impossible. And then it wasn’t.
